{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T04:20:40Z","timestamp":1751516440036,"version":"3.41.0"},"reference-count":114,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.nephro.2017.12.001","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T16:29:23Z","timestamp":1521217763000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["N\u00e9phrotoxicit\u00e9 des antir\u00e9troviraux autres que le t\u00e9nofovir"],"prefix":"10.1684","volume":"14","author":[{"given":"Christopher","family":"Loens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Amet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Isnard-Bagnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Tourret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.12.001_bib1080","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nephro.2016.01.002","article-title":"N\u00e9phrotoxicit\u00e9 du tenofovir","volume":"12","author":"Isnard-Bagnis","year":"2016","journal-title":"N\u00e9phrologie & Th\u00e9rapeutique"},{"key":"10.1016\/j.nephro.2017.12.001_bib0545","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00002030-200402200-00022","article-title":"Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study","volume":"18","author":"Lucas","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0550","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1086\/523729","article-title":"Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease","volume":"45","author":"Choi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0555","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0560","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/QAD.0b013e32831cc129","article-title":"Interruption of antiretroviral therapy is associated with increased plasma cystatin C","volume":"23","author":"Mocroft","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0565","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/QAD.0b013e328307a051","article-title":"Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia","volume":"22","author":"Mulenga","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0570","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/QAI.0b013e3181e674f4","article-title":"The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women","volume":"55","author":"Estrella","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nephro.2017.12.001_bib0575","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1086\/430257","article-title":"Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America","volume":"40","author":"Gupta","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0580","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/QAD.0b013e32830e0152","article-title":"The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis","volume":"22","author":"Wyatt","year":"2008","journal-title":"AIDS"},{"year":"2010","series-title":"GPR antiviraux","author":"Zimner-Rapuch","key":"10.1016\/j.nephro.2017.12.001_bib0585"},{"key":"10.1016\/j.nephro.2017.12.001_bib0590","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00228-009-0660-5","article-title":"Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART","volume":"65","author":"Bertrand","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0595","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/ftd.0b013e318030839e","article-title":"Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults","volume":"29","author":"Collin","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.nephro.2017.12.001_bib0600","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1026132412074","article-title":"The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk","volume":"17","author":"Corsini","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib0605","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1053\/jlts.2002.34880","article-title":"The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients","volume":"8","author":"Jain","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.nephro.2017.12.001_bib0610","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00002030-200202150-00032","article-title":"Probable interaction between efavirenz and cyclosporine","volume":"16","author":"Tseng","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0615","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2215\/CJN.00370705","article-title":"Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists","volume":"1","author":"Berns","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0620","unstructured":"Gilead Science 2006\u00a0annual report on marketed products 2007. http:\/\/www.gilead.com\/AR2006\/hiv_aids.php."},{"key":"10.1016\/j.nephro.2017.12.001_bib0625","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0149-2918(00)90004-3","article-title":"Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity","volume":"22","author":"Kakuda","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib0630","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00002030-200401230-00002","article-title":"Antiretroviral nucleoside and nucleotide analogues and mitochondria","volume":"18","author":"Cossarizza","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0635","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1517\/14656566.4.8.1321","article-title":"Lactic acidosis related to nucleoside therapy in HIV-infected patients","volume":"4","author":"Falco","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nephro.2017.12.001_bib0640","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/QAD.0b013e3282f08cdc","article-title":"Lactic acidosis International Study Group Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy","volume":"21","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0645","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/cc2162","article-title":"Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors","volume":"7","author":"Claessens","year":"2003","journal-title":"Crit Care"},{"key":"10.1016\/j.nephro.2017.12.001_bib0650","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00002030-199301000-00024","article-title":"Dideoxyinosine-associated nephrotoxicity","volume":"7","author":"Crowther","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0655","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1093\/ndt\/gfm467","article-title":"Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review","volume":"22","author":"D\u2019Ythurbide","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2017.12.001_bib0660","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/01.aids.0000168985.05209.b8","article-title":"Fanconi syndrome associated with didanosine therapy","volume":"19","author":"Izzedine","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0665","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1086\/379829","article-title":"Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine","volume":"37","author":"Rollot","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0670","first-page":"296","article-title":"Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome","volume":"52","author":"Ahmad","year":"2006","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0675","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2893.2009.01160.x","article-title":"Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis\u00a0B virus","volume":"17","author":"Tamori","year":"2010","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.nephro.2017.12.001_bib0680","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/QAD.0b013e328303be50","article-title":"Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy","volume":"22","author":"Nelson","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0685","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/ajkd.2000.19114","article-title":"Acute renal failure in an HIV-positive 50-year-old man","volume":"36","author":"Krishnan","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0690","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701\u00a0screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib1085","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.2215\/CJN.09191010","article-title":"New AIDS Data group. Risk factors of chronic kidney disease in HIV-infected patients","volume":"6","author":"Flandre","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5Pt2","key":"10.1016\/j.nephro.2017.12.001_bib0695","first-page":"1094","article-title":"Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus","volume":"101","author":"Knudtson","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0700","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0002-9343(01)01135-4","article-title":"Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine","volume":"112","author":"Castro","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0705","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jinf.2005.05.020","article-title":"Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure","volume":"52","author":"Angel-Moreno-Maroto","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.nephro.2017.12.001_bib0710","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1440-1797.2008.00968.x","article-title":"Renal impairment and hypersensitivity reaction due to efavirenz","volume":"13","author":"Curry","year":"2008","journal-title":"Nephrology"},{"key":"10.1016\/j.nephro.2017.12.001_bib0715","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/QAD.0b013e32801120d1","article-title":"Efavirenz-associated podocyte damage","volume":"21","author":"Barbour","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0720","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1097\/QAD.0b013e3282ef792f","article-title":"Efavirenz urolithiasis","volume":"21","author":"Izzedine","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0725","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00240-006-0052-6","article-title":"Efavirenz-induced urolithiasis","volume":"34","author":"Wirth","year":"2006","journal-title":"Urol Res"},{"key":"10.1016\/j.nephro.2017.12.001_bib0730","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/10895940-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine","volume":"48","author":"Scholler-Gyure","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nephro.2017.12.001_bib0735","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/QAD.0b013e32833032ed","article-title":"Efficacy and safety of TMC278\u00a0in antiretroviral-naive HIV-1\u00a0patients: week\u00a096\u00a0results of a phase\u00a0IIb randomized trial","volume":"24","author":"Pozniak","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0740","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0090-9556(25)06651-6","article-title":"pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs","volume":"23","author":"Lin","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nephro.2017.12.001_bib0745","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-9556(25)06530-4","article-title":"Metabolites of L-735,524, a potent HIV-1\u00a0protease inhibitor, in human urine","volume":"23","author":"Balani","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nephro.2017.12.001_bib0750","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(01)63960-0","article-title":"Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis","volume":"159","author":"Witte","year":"1998","journal-title":"J Urol"},{"issue":"6Pt1","key":"10.1016\/j.nephro.2017.12.001_bib0755","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.lpm.2007.05.042","article-title":"Bilateral papillary necrosis during indinavir treatment","volume":"37","author":"Iba-Ba","year":"2008","journal-title":"Presse Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0760","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s15010-001-1105-y","article-title":"Papillary necrosis associated with the HIV protease inhibitor indinavir","volume":"29","author":"Dieleman","year":"2001","journal-title":"Infection"},{"key":"10.1016\/j.nephro.2017.12.001_bib0765","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00042307-200011000-00004","article-title":"Indinavir urolithiasis","volume":"10","author":"Wu","year":"2000","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0770","unstructured":"European Medicines Agency Indinavir EPAR summary for the public 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000128\/WC500035726.pdf."},{"key":"10.1016\/j.nephro.2017.12.001_bib0775","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(05)62506-8","article-title":"Urinary stones in HIV-1-positive patients treated with indinavir","volume":"349","author":"Daudon","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2017.12.001_bib0780","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0090-4295(97)00401-9","article-title":"Protease inhibitor-induced urolithiasis","volume":"50","author":"Gentle","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.nephro.2017.12.001_bib0785","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0022-5347(01)61596-9","article-title":"Imaging characteristics of indinavir calculi","volume":"161","author":"Schwartz","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0790","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2214\/ajr.171.3.9725303","article-title":"Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy","volume":"171","author":"Blake","year":"1998","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0795","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-5347(05)63936-5","article-title":"The etiology of urolithiasis in HIV infected patients","volume":"169","author":"Nadler","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0800","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/jac\/dkl112","article-title":"The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity","volume":"57","author":"Boyd","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nephro.2017.12.001_bib0805","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00228-007-0343-z","article-title":"Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity","volume":"63","author":"Wasmuth","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0810","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/jac\/dkg198","article-title":"Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients","volume":"51","author":"Burger","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nephro.2017.12.001_bib0815","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/135965350300800407","article-title":"Administration of indinavir and low-dose ritonavir (800\/100mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir","volume":"8","author":"Aarnoutse","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib0820","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11255-006-9154-x","article-title":"Urological management of indinavir-associated acute renal failure in HIV-positive patients","volume":"39","author":"Kalaitzis","year":"2007","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0825","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1086\/517740","article-title":"Persistent nephrolithiasis after discontinuation of indinavir therapy","volume":"27","author":"Polhemus","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0830","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0022-5347(01)61595-7","article-title":"Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed","volume":"161","author":"Reiter","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0835","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000019854","article-title":"Urolithiasis and the protease inhibitor indinavir","volume":"35","author":"Hermieu","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0840","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0022-5347(05)66911-X","article-title":"Increased prevalence and analysis of risk factors for indinavir nephrolithiasis","volume":"164","author":"Saltel","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0845","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJM199701093360215","article-title":"Indinavir nephropathy","volume":"336","author":"Tashima","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0850","first-page":"261","article-title":"Pyuria in patients treated with indinavir is associated with renal dysfunction","volume":"54","author":"Sarcletti","year":"2000","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0855","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/00002030-200109070-00025","article-title":"Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1\u00a0infected children","volume":"15","author":"van Rossum","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0860","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/ajkd.2000.9791","article-title":"Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir","volume":"36","author":"Gagnon","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.nephro.2017.12.001_bib0865","first-page":"S21","article-title":"High prevalence of indinavir-associated renal complications in Thai HIV-infected patients","volume":"89","author":"Avihingsanon","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.nephro.2017.12.001_bib0870","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00126334-200302010-00004","article-title":"Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir","volume":"32","author":"Dieleman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nephro.2017.12.001_bib0875","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0022-5347(05)67739-7","article-title":"Urinary cytology changes in protease inhibitor induced urolithiasis","volume":"163","author":"Hamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0880","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7326\/0003-4819-127-2-199707150-00004","article-title":"Crystalluria and urinary tract abnormalities associated with indinavir","volume":"127","author":"Kopp","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0885","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1097\/00002030-200210180-00019","article-title":"Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir dose\/body mass index","volume":"16","author":"Meraviglia","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0890","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/135965350000500105","article-title":"Increased incidence of indinavir nephrolithiasis in patients with hepatitis\u00a0B or C virus infection","volume":"5","author":"Malavaud","year":"2000","journal-title":"Antivir Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib0895","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1086\/520226","article-title":"Influence of environmental temperature on incidence of indinavir-related nephrolithiasis","volume":"29","author":"Martinez","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0900","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0090-4295(97)00399-3","article-title":"Urolithiasis associated with the protease inhibitor indinavir","volume":"50","author":"Bruce","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.nephro.2017.12.001_bib0905","doi-asserted-by":"crossref","first-page":"E748","DOI":"10.1503\/cmaj.100019","article-title":"Medication-based urolithiasis and atazanavir","volume":"183","author":"Koblic","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.nephro.2017.12.001_bib0910","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jinf.2011.02.004","article-title":"Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients","volume":"62","author":"Fabbiani","year":"2011","journal-title":"J Infect"},{"key":"10.1016\/j.nephro.2017.12.001_bib0915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1179\/joc.2008.20.1.143","article-title":"Urolithiasis under atazanavir boosted and tenofovir therapy: a case report","volume":"20","author":"D\u2019Ettorre","year":"2008","journal-title":"J Chemother"},{"key":"10.1016\/j.nephro.2017.12.001_bib0920","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/QAD.0b013e3280c56ae1","article-title":"Atazanavir-containing renal calculi in an HIV-infected patient","volume":"21","author":"Anderson","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0925","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMc061892","article-title":"Atazanavir urolithiasis","volume":"355","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib0930","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/01.aids.0000247571.88256.90","article-title":"Atazanavir urinary stones in an HIV-infected patient","volume":"20","author":"Pacanowski","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0935","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jana.2007.11.005","article-title":"Case presentation: nephrolithiasis in a patient treated with atazanavir","volume":"19","author":"Savini","year":"2008","journal-title":"J Assoc Nurses AIDS Care"},{"key":"10.1016\/j.nephro.2017.12.001_bib0940","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00240-008-0147-3","article-title":"Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient","volume":"36","author":"Moriyama","year":"2008","journal-title":"Urol Res"},{"key":"10.1016\/j.nephro.2017.12.001_bib0945","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1086\/521930","article-title":"Urolithiasis in HIV-positive patients treated with atazanavir","volume":"45","author":"Couzigou","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0950","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/QAD.0b013e32813aee35","article-title":"Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System","volume":"21","author":"Chan-Tack","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0955","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1097\/QAD.0b013e3282f17503","article-title":"Atazanavir crystal nephropathy","volume":"21","author":"Izzedine","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0960","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3851\/IMP1700","article-title":"Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir","volume":"16","author":"Viglietti","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib0965","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00002030-200403050-00022","article-title":"Lopinavir-ritonavir (Kaletra\u00ae) and lithiasis: seven cases","volume":"18","author":"Doco-Lecompte","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib0970","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/135965350801300514","article-title":"Same patient, new stone composition: amprenavir urinary stone","volume":"13","author":"Feicke","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib0975","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0022-5347(05)65307-4","article-title":"Nelfinavir urinary stones","volume":"167","author":"Engeler","year":"2002","journal-title":"J Urol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.nephro.2017.12.001_bib0980","first-page":"60","article-title":"Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature","volume":"75","author":"Shafi","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nephro.2017.12.001_bib0985","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1086\/425917","article-title":"Pharmacokinetics of enfuvirtide in a patient with impaired renal function","volume":"39","author":"Leen","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib0990","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/QAI.0b013e31816237f0","article-title":"Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function","volume":"47","author":"Tebas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nephro.2017.12.001_bib0995","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1\u00a0fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib1000","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jinf.2010.04.011","article-title":"Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution","volume":"61","author":"Masia","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.nephro.2017.12.001_bib1005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1258\/ijsa.2010.010246","article-title":"Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature","volume":"21","author":"Croce","year":"2010","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib1010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAD.0b013e328334cc4a","article-title":"A case of rhabdomiolysis associated with raltegravir use","volume":"24","author":"Dori","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib1015","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/QAD.0b013e328303be40","article-title":"Severe rhabdomyolysis associated with raltegravir use","volume":"22","author":"Zembower","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.nephro.2017.12.001_bib1090","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.01194-08","article-title":"Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics","volume":"53","author":"Iwamoto","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nephro.2017.12.001_bib1020","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"Zolopa","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib1025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48\u00a0week results from SPRING-1, a dose-ranging, randomised, phase\u00a02b trial","volume":"12","author":"van Lunzen","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nephro.2017.12.001_bib1095","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"GS-US-292-0112\u00a0Study Team. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase\u00a03\u00a0study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nephro.2017.12.001_bib1100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/QAI.0000000000001186","article-title":"Brief report: Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase\u00a03\u00a0study","volume":"74","author":"Post","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nephro.2017.12.001_bib1105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nephro.2017.12.001_bib1125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00228-013-1590-9","article-title":"Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment","volume":"70","author":"Weller","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"issue":"suppl\u00a01","key":"10.1016\/j.nephro.2017.12.001_bib1035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.2008.03137.x","article-title":"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects","volume":"65","author":"Abel","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nephro.2017.12.001_bib1040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11319470-000000000-00000","article-title":"Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen","volume":"49","author":"Kasserra","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nephro.2017.12.001_bib1045","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.4049\/jimmunol.179.4.2289","article-title":"CCR5\u00a0blockade modulates inflammation and alloimmunity in primates","volume":"179","author":"Schroder","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.nephro.2017.12.001_bib1110","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11904-014-0212-1","article-title":"Drug interactions and antiretroviral drug monitoring","volume":"11","author":"Foy","year":"2014","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.nephro.2017.12.001_bib1115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"ARTEN investigators. Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1\u00a0patients: the ARTEN Trial","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.nephro.2017.12.001_bib1120","doi-asserted-by":"crossref","first-page":"e1001236","DOI":"10.1371\/journal.pmed.1001236","article-title":"OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208\/OCTANE Study Team. Nevirapine- vs lopinavir\/ritonavir-based initial therapy for HIV-1\u00a0infection among women in Africa: a randomized trial","volume":"9","author":"Lockman","year":"2012","journal-title":"Plos Med"},{"key":"10.1016\/j.nephro.2017.12.001_bib1050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/14656566.2010.509345","article-title":"Recent advances in antiretroviral drugs","volume":"12","author":"Ghosh","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nephro.2017.12.001_bib1055","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5\u00a0monoclonal antibody PRO 140\u00a0administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nephro.2017.12.001_bib1070","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2012.06.063","article-title":"HIV and coronary heart disease: time for a better understanding","volume":"61","author":"Boccara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2017.12.001_bib1075","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/QAD.0b013e3280d3587f","article-title":"Microalbuminuria in HIV infection","volume":"21","author":"Szczech","year":"2007","journal-title":"AIDS"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517306351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517306351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.12.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T21:06:11Z","timestamp":1751490371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517306351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1769725517306351"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.12.001","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9phrotoxicit\u00e9 des antir\u00e9troviraux autres que le t\u00e9nofovir","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}